IceCure shares are trading lower after the company announced the FDA has at this time denied its De Novo Classification request for breast cancer which was submitted based on interim analysis from its ICE3 study.
Portfolio Pulse from Benzinga Newsdesk
IceCure's shares are trading lower following the FDA's denial of its De Novo Classification request for breast cancer, which was based on interim analysis from its ICE3 study.
September 20, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
IceCure's stock price is experiencing a downturn due to the FDA's denial of its De Novo Classification request for breast cancer.
The FDA's denial of IceCure's De Novo Classification request is a significant setback for the company, as it hampers the company's progress in developing a new treatment for breast cancer. This negative news is likely to shake investor confidence, leading to a decrease in the company's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100